%0 Journal Article
%T Exploratory study on the impact of switching to nilotinib in 18 patients with chronic myeloid leukemia in chronic phase with suboptimal response to imatinib
%A Anand Jillella
%A Carole B. Miller
%A Daniel J. DeAngelo
%A Felice Lin
%A Ghulam Warsi
%A Jerald Radich
%A Luke P. Akard
%A Sikander Ailawadhi
%A Solveig G. Ericson
%J Archive of "Therapeutic Advances in Hematology".
%D 2017
%R 10.1177/2040620716678118
%X The phase II, exploratory, open-label Exploring Nilotinib BCR-ABL Effects (ENABL) study [ClinicalTrials.gov identifier: {"type":"clinical-trial","attrs":{"text":"NCT00644878","term_id":"NCT00644878"}}NCT00644878] assessed the impact of switching to nilotinib therapy in patients with chronic myeloid leukemia in chronic phase (CML-CP) who had a suboptimal molecular response with imatinib
%K CML-CP
%K ENABL
%K imatinib
%K nilotinib
%K suboptimal response
%K switch
%K tyrosine kinase inhibitor
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5167080/